Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
53°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
26.03
+0.01 (+0.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis Inc
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Post-Fed Thursday
January 06, 2022
Companies earning in dollars but incorporated abroad and paying dividends in other currencies were big gainers today.
Via
Talk Markets
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
January 06, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
January 05, 2022
From
Exelixis, Inc.
Via
Business Wire
The Sunday File for Nov. 21
November 21, 2021
Good news and bad - making up for the short week by getting a Sunday start.
Via
Talk Markets
Analyst Ratings For Exelixis
November 03, 2021
Over the past 3 months, 5 analysts have published their opinion on Exelixis (NASDAQ:
Via
Benzinga
Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022
January 04, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
January 04, 2022
From
Exelixis, Inc.
Via
Business Wire
7 of the Best Cheap Stocks Under $20 for 2022 to Buy Now
January 03, 2022
These cheap stocks are trading at highly attractive prices and have the potential to break through this year.
Via
InvestorPlace
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
December 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...
Via
Benzinga
Exelixis Elects Jacqueline Wright to Its Board of Directors
December 17, 2021
From
Exelixis, Inc.
Via
Business Wire
Uncertain Times
December 15, 2021
The UK inflation rate last month was 5.1%, not a good omen.
Via
Talk Markets
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
December 15, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021
November 20, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer
November 09, 2021
From
Exelixis, Inc.
Via
Business Wire
3 No-Brainer Biotech Stocks to Buy in November
November 04, 2021
Here are three Motley Fool contributors' top picks.
Via
The Motley Fool
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December
November 03, 2021
From
Exelixis, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 03, 2021
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion...
Via
Benzinga
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
November 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...
Via
Benzinga
Topics
Retirement
Exposures
Pension
Exelixis, inc (EXEL) Q3 2021 Earnings Call Transcript
November 02, 2021
EXEL earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Exelixis: Q3 Earnings Insights
November 02, 2021
Exelixis (NASDAQ:EXEL) reported its Q3 earnings results on Tuesday, November 2, 2021 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis...
Via
Benzinga
Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 02, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Earnings Perspective: Return On Capital Employed
November 02, 2021
According to Benzinga Pro, during Q2, Exelixis (NASDAQ:EXEL) earned $123.01 million, a 2770.02% increase from the preceding quarter. Exelixis also posted a total of $385.18...
Via
Benzinga
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
Exposures
COVID-19
Here's My Top Value Stock To Buy Right Now
November 01, 2021
EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications.
Via
Talk Markets
Down 76%: Is Cortexyme Stock a Bargain?
October 28, 2021
The biotech's stock took a big hit after its lead product candidate flunked a key clinical trial.
Via
The Motley Fool
Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
October 19, 2021
From
Exelixis, Inc.
Via
Business Wire
EVP And Scientific Strategy Cso Of Exelixis Trades $1.3M In Company Stock
October 18, 2021
Peter Lamb, EVP And Scientific Strategy Cso at Exelixis (NASDAQ:EXEL), made a large buy and sell of company shares on October 15, according to a new SEC filing. What Happened: A...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
More Chinese Trouble
October 14, 2021
A day after the consumer price rise there was another price rise for producer markets.
Via
Talk Markets
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
October 14, 2021
From
Exelixis, Inc.
Via
Business Wire
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.